
US-based GE Healthcare and Danish Minerva Imaging have entered into a strategic partnership "to accelerate precision medicine and targeted radionuclide therapy," a press release announces.
Radionuclide therapy, which is a type of precision medicine, entails a radioactive substance being administered into the bloodstream to target and irradiate cancer cells. The therapy is designed to reduce the potential side effects compared to traditional cancer treatments.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app